Mohamed Ali Elbaiomy

@mans.edu.eg

Mansoura University

Mohamed Ali Elbaiomy


            Download Compact PDF  
https://researchid.co/malibasha1
12

Scopus Publications

420

Scholar Citations

11

Scholar h-index

13

Scholar i10-index

Scopus Publications

  • CLINICAL OUTCOMES AND PROGNOSTIC FEATURES OF GERMLINE BRCA MUTANT BREAST CANCER PATIENTS: SINGLE-CENTER EXPERIENCE, MADINAH, SAUDI ARABIA
    World Cancer Research Journal, 2025
  • Comparing Ribociclib versus Palbociclib as a Second Line Treatment in Combination with Fulvestrant in Metastatic Breast Cancer: A Randomised Clinical Trial
    Manar Hamed Ahmed Shaaban, Mohamed Ali Elbaiomy, Ahmed Eltantawy, Abdel-Hady El- Gilany Abdel-Fattah, Sameh Shamaa
    Asian Pacific Journal of Cancer Prevention, 2024
  • ALL-017 Adult T-Cell Acute Lymphoblastic Leukemia With Transducin-Like Enhancer Gene Expression
    Mohamed Elbaiomy, Mohamed Sabry
    Clinical Lymphoma Myeloma and Leukemia, 2022
  • ABCL-310 Triple Metachronous Malignancies in Primary Diagnosed Diffuse Large B-Cell Lymphoma Patient: A Case Report
    Salma Elashwah, Hadeer Elsaeed AboElfarh, Sara Atwa, Samar Attia, M.A. ElBaiomy, et al.
    Clinical Lymphoma Myeloma and Leukemia, 2022
  • ABCL-175 Bilharzial Colitis Post-Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma Patient: A Case Report
    Shaimaa El-Ashwah, Noreen Elbayoumi, May Denewer, Mohamed ELboghdady, Emad Azmy, et al.
    Clinical Lymphoma Myeloma and Leukemia, 2022
  • Molecular Mechanisms Mediating Ceftazidime/ Avibactam Resistance Amongst Carbapenem-Resistant Klebsiella pneumoniae Isolates from Cancer Patients
    Rania Abd El-Hamid El-Kady, Mohamed Ali Elbaiomy, Rasha Mokhtar Elnagar
    Infection and Drug Resistance, 2022
  • Repurposing metformin as anticancer drug: Randomized controlled trial in advanced prostate cancer (MANSMED)
    Reham Alghandour, Mohamed A. Ebrahim, Ahmed M. Elshal, Fady Ghobrial, Maha Elzaafarany, et al.
    Urologic Oncology Seminars and Original Investigations, 2021
    BACKGROUND The proposal of metformin as an anticancer drug has been explored in many types of cancers. Metformin may act synergistically with standard prostate cancer therapies. However, there is still a debate about the effect of metformin on hormone sensitive prostate cancer (HSPC). PATIENTS AND METHODS randomized controlled trial. Eligible patients were high risk locally advanced or metastatic HSPC. Patients were randomly assigned to receive either metformin plus standard of care or standard of care alone. The primary endpoint was castration-resistant prostate cancer-free survival (CRPC-FS). The secondary endpoints were overall survival, PSA level and adverse events. RESULTS A total number of 124 patients underwent randomization where 62 patients were allocated in each arm. Over a median follow up of 22 months, the CRPC-FS was significantly improved with metformin (29 months, 95% CI 25-33 vs. 20 months 95% CI 16-24; P = 0.01). After subgroup analysis, the addition of metformin improved the CRPC-FS in patients with high risk localized disease (median not reached vs. 25 months, 95% CI 18-31; P = 0.02) and in patients with metastatic low tumor volume disease (median not reached vs. 15 months, 95% CI 5-25; P = 0.009). No significant difference in overall survival or PSA response in both treatment arms (P = 0.1 and 0.5, respectively). Metformin was not associated with significant adverse events apart from grade II diarrhea. CONCLUSION Metformin is a safe and low-cost drug. Combining with androgen deprivation therapy improves the outcome in locally advanced or metastatic prostate cancer. Patients with low volume metastatic prostate cancer seem to drive more benefit.
  • Suggested modifications to the management of patients with breast cancer during the covid-19 pandemic:web-based survey study
    Shereef Elsamany, Mohamed Elbaiomy, Ahmed Zeeneldin, Emad Tashkandi, Fayza Hassanin, et al.
    Jmir Cancer, 2021
    Background Management of patients with cancer in the current era of the COVID-19 pandemic poses a significant challenge to health care systems. Breast cancer is the most common cancer internationally. Breast cancer is a disease that involves surgery, chemotherapy, hormonal therapy, targeted therapy, radiotherapy, and, more recently, immunotherapy in its management plan. The immune system requires months to recover from these medications, and this condition is even worse in patients with metastatic breast cancer who need ongoing treatment with these drugs. Some of these drugs, such as inhibitors of cyclin-dependent kinases 4 and 6, can cause rare but life-threating lung inflammation. Patients with breast cancer who have metastatic disease to the lungs can experience deterioration of disease symptoms with COVID-19 infection. Oncologists treating patients with breast cancer are facing a difficult situation regarding treatment choice. The impact that COVID-19 has had on breast cancer care is unknown, including how to provide the best care possible without compromising patient and community safety. Objective The aim of this study was to explore the views of oncologists regarding the management of patients with breast cancer during the COVID-19 pandemic. Methods A web-based SurveyMonkey questionnaire was submitted to licensed oncologists involved in breast cancer management in Saudi Arabia, Egypt, and United Arab Emirates. The survey focused on characteristics of the participants, infection risk among patients with cancer, and possible treatment modifications related to different types of breast cancer. Results The survey was completed by 82 participants. For early hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer, 61 of the 82 participants (74%) supported using neoadjuvant hormonal therapy in selected patients, and 58% (48/82) preferred giving 6 over 8 cycles of adjuvant chemotherapy when indicated. Only 43% (35/82) preferred inhibitors of cyclin-dependent kinases 4 and 6 with hormonal therapy as the first-line treatment in all patients with metastatic HR-positive disease. A total of 55 of the 82 participants (67%) supported using adjuvant trastuzumab for 6 instead of 12 months in selected patients with HER2-positive breast cancer. For metastatic HER2-positive, HR-positive breast cancer, 80% of participants (66/82) supported the use of hormonal therapy with dual anti-HER2 blockade in selected patients. The preferred choice of first-line treatment in metastatic triple negative patients with BRCA mutation and programmed cell death 1 ligand 1 (PD-L1) <1% was poly(adenosine diphosphate–ribose) polymerase inhibitor according to 41% (34/82) of the participants, and atezolizumab with nab-paclitaxel was preferred for PD-L1 >1% according to 71% (58/82) of the participants. Conclusions Several modifications in breast cancer management were supported by the survey participants. These modifications need to be discussed on a local basis, taking into account the local infrastructure and available resources.
  • Prognostic Value of TLE1 Gene Expression in Patients with T-cell Acute Lymphoblastic Leukemia
    Salah Aref, Mohamed Sabry El-Ghonemy, Doaa Mohamed Atia, Mohamed Elbaiomy, Sherehan Abdelsalam, et al.
    Asian Pacific Journal of Cancer Prevention, 2021
    BACKGROUND Transducin-like enhancer of split 1 (TLE1( is a member of the TLE family of transcriptional co-repressors that control the transcription of a wide range of genes. The aim of this study was to evaluate the prognostic role of TLE1 gene expression in patients with T-cell acute lymphoblastic leukemia (T-ALL). METHOD This study was conducted on 97 newly diagnosed T-ALL patients admitted to the Mansoura University oncology center (59 males and 38 females) with median age (33 years) in addition to 102 apparently healthy individuals served as a control group. TLE1 gene expression was measured in both patients and control groups by real time - PCR. The calculation of relative gene expression was done using the ΔΔCt method. RESULTS TEL1 gene expression was significantly down regulated in T-ALL cases (median 2.83) as compared to controls (median 84.65) (p < 0.001). The low TEL1 gene expression was significantly associated with CNS infiltration, non-remission and higher relapse rate (p < 0.001, 0.001 and 0.023 respectively). Likewise, Low TEL1 gene expression was significantly associated with shorter OS and DFS (P= 0.012 and 0.011 respectively). Furthermore, Low TEL1 gene expression was considered as risk predictor of relapse with OR 3.636(CI.1.422-9.295) (P =0.007); and OR 0.803(CI. 0.609-0.96) (P=0.021) and independent predictor of T-ALL patient's outcome with OR 0.619 (CI. 0.44-0.872) (P=0.006). CONCLUSION TLE1 gene expression was significantly down regulated in T-ALL cases as compared with controls. Low TLE1 expression is independent predictor of the T-ALL patient's outcome..
  • Osteopontin level and promoter polymorphism in patients with metastatic breast cancer
    M.A. Elbaiomy, T. Akl, R. Elhelaly, W. El-Beshbishi, M.S. El Ghonemy, et al.
    Current Oncology, 2020
    Background: Cancer initiation typically occurs when a proto-oncogene’s coding region undergoes mutation, resulting in uncontrollable cell growth and division, or when a tumour suppressor gene’s coding region is affected by a mutation that inhibits activity of the resulting gene product. The pathophysiologic result is, respectively, exaggerated cell-cycle growth or deficient programmed cell death. Osteopontin (opn) is an integrin-binding phosphoprotein that is expressed on the surface of normal cells. Osteopontin has a major role in diverse tumour components, especially those implicated in invasion and metastasis. In the present study, we aimed to illustrate the value of opn as a possible contributor in breast cancer (bca). Methods: This prospective study included 115 patients newly diagnosed with bca and distant metastasis who were recruited from the Oncology Center, Mansoura University, and the Department of Clinical Oncology and Nuclear Medicine, Mansoura University Hospital, Egypt. The patients recruited had been diagnosed with disseminated visceral metastasis (visceral crisis), with or without bone metastasis; patients with cranial metastasis were excluded from the study. All patients received first-line chemotherapy with docetaxel 75 mg/m2 plus cisplatin 75 mg/m2 or carboplatin 6 auc (area under the curve) on day 1 every 21 days for a maximum of 6 cycles or till development of toxicity. Trastuzumab (in cases of her2-positive disease) was given whenever possible (if government assistance or personal finances permitted). Serum levels of opn were assessed by enzyme-linked immunosorbent assay (elisa) before treatment was started. A group of 30 matched healthy women whose median serum opn level was 15 ng/dL were included, and that level was therefore defined as the cut-off value. In addition, opn gene mutation was determined by polymerase chain reaction (pcr). Correlations of pretreatment serum opn and opn gene mutation with various patient clinicopathologic variables, response to the treatment, progression-free survival (pfs), and overall survival (os) were assessed. Results: Mean serum opn was highest in her2-amplified bca (64.4 ± 42.3 ng/dL), and then in triple-negative bca (55.9 ± 34.7 ng/dL), followed by the luminal B and A subtypes (38.4 ± 33.1 ng/dL and 36.3 ± 32.2 ng/dL respectively, p = 0.017). Testing by pcr revealed that opn gene mutation was highest in triple-negative bca (85% opn mutant vs. 15% non-mutant), and then in her2-overexpressed bca (80% opn mutant vs. 20% non-mutant), followed by luminal B bca (61.9% opn mutant vs. 38.1% non-mutant); the least expression was detected in luminal A bca (57.9% opn mutant vs. 42.1% non-mutant). Interestingly, patients with high serum opn and opn gene mutation experienced both poor pfs (median: 12 months vs. 14 months; p = 0.001) and poor os (median: 14 months vs. 18 months; p = 0.001). Moreover, participants with opn gene mutation experienced a poor response: of those with progressive disease, 74% had opn mutation and 26% had unmutated opn (p = 0.04). Additionally, high pretreatment serum opn was correlated with poor treatment response: 49.1 ± 33.8 ng/dL in patients with progressive disease and 35.5 ± 34.3 ng/dL in those who achieved a complete response, a partial response, or stable disease (p = 0.05). Strong concordance was found between high serum opn and opn gene mutation in 69 tumours (79.3%), and strong concordance was detected between normal or low serum opn and non-mutant opn in 28 tumours (60.8%). Conclusions: The current prospective work helps to highlight opn as a valid prognostic biomarker for patients with metastatic bca and reveals that high pretreatment serum opn and opn gene mutation are both strongly linked with poor response and survival. Concordance between elisa and pcr results indicates that either method can be used for the evaluation of opn. Increased opn gene mutation in triple-negative bca could assist in tailoring the treatment response in this very aggressive tumour subtype and could be considered a targetable molecule in future studies.
  • Clinical Impact of Breast Cancer Stem Cells in Metastatic Breast Cancer Patients
    M. A. Elbaiomy, Tamer Akl, Nadia Atwan, Ahmed Ali Elsayed, Maha Elzaafarany, et al.
    Journal of Oncology, 2020
  • Prognostic Impact of Lymphoid Enhancer Factor 1 Expression and Serum Galectin.3 in Egyptian AML Patients
    M. A. ElBaiomy, S. Aref, M. El Zaafarany, Sara Atwa, Tamer Akl, et al.
    Advances in Hematology, 2019

RECENT SCHOLAR PUBLICATIONS

  • Investigation of solution-regulated mineralization of bioactive glass using solid-state nuclear magnetic resonance
    M El Baiomy, L Hu, Y Xu, J Ren
    Journal of the European Ceramic Society, 118467 , 2026
    2026
  • ALL-076: Clinical and Prognostic Impact of PI3K Mutation and IL10 G1082A in Egyptian Patients With T-Cell Acute Lymphoblastic Leukemia: A Single-Center Experience
    M ElBaiomy, M El-Ghonemy
    Clinical Lymphoma Myeloma and Leukemia 25, S336-S337 , 2025
    2025
  • POSTER: ALL-076 Clinical and Prognostic Impact of PI3K Mutation and IL10 G1082A in Egyptian Patients With T-Cell Acute Lymphoblastic Leukemia: A Single-Center Experience
    M ElBaiomy, M El-Ghonemy
    Clinical Lymphoma Myeloma and Leukemia 25, S167 , 2025
    2025
  • MM-095 Safety and Efficacy of Dexamethasone for Prevention of Engraftment Syndrome in a Patient With Multiple Myeloma Undergoing ASCT: A Single-Center Experience
    AR Elsergany, S Shamaa, M Awad, M Ibrahim, T Elkhodary, ...
    Clinical Lymphoma Myeloma and Leukemia 24, S535-S536 , 2024
    2024
    Citations: 1
  • Prognostic Values of PDL-1 and IL-10 (G1082A) in Egyptian Patients With Acute Lymphoblastic Leukemia: A Single-Centre Study
    M Elbaiomy, M Elghonemy
    Clinical Lymphoma Myeloma and Leukemia 24, S157 , 2024
    2024
  • ALL-035 Prognostic values of PDL-1 and IL-10 (G1082A) in Egyptian patients with acute lymphoblastic leukemia: A singlecentre study
    M Elbaiomy, M Elghonemy
    Clinical Lymphoma Myeloma and Leukemia 24, S257 , 2024
    2024
  • Exploring the effect of Er2O3 content on the structural, thermal, and physical characteristics of zinc silicate glasses
    M El Baiomy, RM Ramadan, YM Moustafa, G El Damrawi
    Materials Chemistry and Physics 323, 129636 , 2024
    2024
    Citations: 12
  • Calcium silicate glass ceramics containing chromium sulfate: structural, optical, and shielding properties
    MA Madshal, G El-Damrawi, M El Baiomy, A Behairy
    Arabian Journal for Science and Engineering 49 (7), 10147-10161 , 2024
    2024
    Citations: 7
  • Structural, optical, and radiation shielding parameters of zinc silicate glasses modified with erbium oxide
    M El Baiomy, RM Ramadan, YM Moustafa, G El Damrawi
    Optical Materials 152, 115529 , 2024
    2024
    Citations: 11
  • 214P Comparing ribociclib versus palbociclib as a second-line treatment in combination with fulvestrant in metastatic breast cancer: A randomised clinical trial
    M Hamed, SSA Shamaa, A Eltantawy, MA Elbaiomy, AH El-Gilany
    ESMO Open 9 , 2024
    2024
  • Comparing ribociclib versus palbociclib as a second line treatment in combination with fulvestrant in metastatic breast cancer: a randomized clinical trial
    MHA Shaaban, MA Elbaiomy, A Eltantawy, AHEG Abdel-Fattah, ...
    Asian Pacific Journal of Cancer Prevention: APJCP 25 (9), 3039 , 2024
    2024
    Citations: 3
  • Gemox-Vinorelbine as Pre-Transplant Salvage in Diffuse Large B Cell Non-Hodgkin Lymphoma Patients Single Institutional Prospective Phase II Study.
    S Atwa, MA ElBaiomy, M Abdelhakiem, M Salah-Eldin
    Journal of Advanced Zoology 44 , 2023
    2023
  • CT-136 The Clinical Outcome of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Coinfection After Autologous Stem Cell Transplantation in Egyptian Patients With Multiple …
    S Elashwah, MA ElBaiomy, M Samra, S El-Ashwah, R Abdelfattah, ...
    Clinical Lymphoma Myeloma and Leukemia 23, S519 , 2023
    2023
    Citations: 1
  • POSTER: CT-136 The Clinical Outcome of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Coinfection After Autologous Stem Cell Transplantation in Egyptian Patients With …
    S Elashwah, MA ElBaiomy, M Samra, S El-Ashwah, R Abdelfattah, ...
    Clinical Lymphoma Myeloma and Leukemia 23, S229 , 2023
    2023
  • PB2419: THE OUTCOME OF VIRAL HEPATITIS-C INFECTION ON HEMATOLOGICAL MALIGNANCIES AFTER AUTOLOGOUS BONE MARROW TRANSPLANTATION IN EGYPT
    S Elashwah, MA Elbaiomy, M Samra, S El-Ashwah, R Abdelfattah, ...
    HemaSphere 7 (S3), e842433a , 2023
    2023
  • P-8 Circulating tumor DNA could have impact on risk assessment and personalizing adjuvant therapy in localized colon cancer
    M Elbaiomy, M Sabry
    Annals of Oncology 34, S16 , 2023
    2023
    Citations: 2
  • The prognostic values of the IL-10 (G1082A) and TNF-α (G308A) polymorphisms in Egyptian patients with acute lymphoblastic leukemia: A single-center study
    MA El Baiomy, T Akl, N ElMenshawy, AH El-Sebaie, H Morkos, ...
    Indian Journal of Cancer 60 (2), 217-223 , 2023
    2023
    Citations: 4
  • Prognostic impact of IL17 a gene polymorphismson Egyptian patients with multiple myeloma
    MI Mortada, D Shahin, N Abousamra, DA Aladle, S El-Ashwah, ...
    Asian Pacific journal of cancer prevention: APJCP 24 (7), 2421 , 2023
    2023
    Citations: 1
  • Expression of PI3K-AKT-mTOR signaling pathway in gastric cancer
    RAD Dardor, S Moniem, M Elbaiomy, N Megahed, HR Shabana
    Gastroenterology hepatology 14, 71-77 , 2023
    2023
    Citations: 2
  • Correction to: Structural Characterization of Strontium Silicate Glasses and Glass Ceramics Applied as Glass Ionomer Cements (GICs)
    G El Damrawi, M El Baiomy, RM Ramadan
    Silicon 14 (16), 11049-11049 , 2022
    2022
    Citations: 1

MOST CITED SCHOLAR PUBLICATIONS

  • Repurposing metformin as anticancer drug: Randomized controlled trial in advanced prostate cancer (MANSMED)
    R Alghandour, MA Ebrahim, AM Elshal, F Ghobrial, M Elzaafarany, ...
    Urologic Oncology: Seminars and Original Investigations 39 (12), 831. e1-831 … , 2021
    2021
    Citations: 60
  • Clinical impact of breast cancer stem cells in metastatic breast cancer patients
    MA Elbaiomy, T Akl, N Atwan, AA Elsayed, M Elzaafarany, S Shamaa
    Journal of oncology 2020 (1), 2561726 , 2020
    2020
    Citations: 47
  • Prevalence and clinical effect of IDH1 and IDH2 mutations among cytogenetically normal acute myeloid leukemia patients
    S Aref, MFA Aaal, OM Adam, MS El-Ghonemy, MA El-Baiomy, ...
    Clinical Lymphoma Myeloma and Leukemia 15 (9), 550-555 , 2015
    2015
    Citations: 44
  • Mammographic breast density: predictive value for pathological response to neoadjuvant chemotherapy in breast cancer patients
    S Elsamany, A Alzahrani, WN Abozeed, A Rasmy, MU Farooq, ...
    The Breast 24 (5), 576-581 , 2015
    2015
    Citations: 42
  • ERCC1 expression in metastatic triple negative breast cancer patients treated with platinum-based chemotherapy
    MAEL Baiomy, WF El Kashef
    Asian Pacific journal of cancer prevention: APJCP 18 (2), 507 , 2017
    2017
    Citations: 34
  • Correlation of preoperative Ki67 and serum CA15. 3 levels with outcome in early breast cancers a multi institutional study
    A Rasmy, W Abozeed, S Elsamany, M El Baiomy, A Nashwa, A Amrallah, ...
    Asian Pacific Journal of Cancer Prevention 17 (7), 3595-3600 , 2016
    2016
    Citations: 30
  • Molecular Mechanisms Mediating Ceftazidime/Avibactam Resistance Amongst Carbapenem-Resistant Klebsiella pneumoniae Isolates from Cancer Patients
    RAEH El-Kady, MA Elbaiomy, RM Elnagar
    Infection and Drug Resistance, 5929-5940 , 2022
    2022
    Citations: 17
  • Osteopontin level and promoter polymorphism in patients with metastatic breast cancer
    MA Elbaiomy, T Akl, R Elhelaly, W El-Beshbishi, MS El Ghonemy, ...
    Current Oncology 27 (5), e444 , 2020
    2020
    Citations: 15
  • Effect of SrO on the Structure of Apatite and Wollastonite Phases of Na2O-CaO-SiO2-P2O5 Glass System
    G El Damrawi, RM Ramadan, M El Baiomy
    New Journal of Glass and Ceramics 11, 45-56 , 2021
    2021
    Citations: 13
  • Exploring the effect of Er2O3 content on the structural, thermal, and physical characteristics of zinc silicate glasses
    M El Baiomy, RM Ramadan, YM Moustafa, G El Damrawi
    Materials Chemistry and Physics 323, 129636 , 2024
    2024
    Citations: 12
  • Structural, optical, and radiation shielding parameters of zinc silicate glasses modified with erbium oxide
    M El Baiomy, RM Ramadan, YM Moustafa, G El Damrawi
    Optical Materials 152, 115529 , 2024
    2024
    Citations: 11
  • Clinicopathologic effect of DNMT3A mutation in adult T-cell acute lymphoblastic leukemia
    S Aref, N El Menshawy, MS El-Ghonemy, T Abou Zeid, MA El-Baiomy
    Clinical Lymphoma Myeloma and Leukemia 16 (1), 43-48 , 2016
    2016
    Citations: 11
  • Telomerase reverse transcriptase ( TERT ) A1062T mutation as a prognostic factor in Egyptian patients with acute myeloid leukemia (AML)
    S Aref, MS El-Ghonemy, TE Abouzeid, AM El-Sabbagh, MA El-Baiomy
    Medical Oncology 31 (9), 158 , 2014
    2014
    Citations: 10
  • Calcium silicate glass ceramics containing chromium sulfate: structural, optical, and shielding properties
    MA Madshal, G El-Damrawi, M El Baiomy, A Behairy
    Arabian Journal for Science and Engineering 49 (7), 10147-10161 , 2024
    2024
    Citations: 7
  • Prognostic value of TLE1 gene expression in patients with T-cell acute lymphoblastic leukemia
    S Aref, MS El-Ghonemy, DM Atia, MM Elbaiomy, SA Abdelsalam, A Tawfik, ...
    Asian Pacific journal of cancer prevention: APJCP 22 (5), 1653 , 2021
    2021
    Citations: 7
  • Prognostic relevance of CD69 expression in B cell chronic lymphocytic leukemia
    S Aref, N El Menshawy, MS El-Ghonemy, G El-Said, MA El-Baiomy
    Comparative Clinical Pathology 28 (1), 33-40 , 2019
    2019
    Citations: 7
  • Structural Characterization of Strontium Silicate Glasses and Glass Ceramics Applied as Glass Ionomer Cements (GICs)
    G El Damrawi, M El Baiomy, RM Ramadan
    Silicon 14 (14), 8733-8743 , 2022
    2022
    Citations: 5
  • 617MO Repurposing metformin as an anticancer drug: preliminary results of randomized controlled trial in advanced prostate cancer (MANSMED)
    R Alghandour, MA Ebrahim, AM Elshal, F Ghobrial, M Elzaafarany, ...
    Annals of Oncology 31, S511 , 2020
    2020
    Citations: 5
  • Thrombophilic risk of factor V Leiden, Prothrombin G20210A, MTHFR, and Calreticulin mutations in essential thrombocythemia egyptian patients
    MS El-Ghonemy, S El Sharawy, MW Fahmi, S El-Ashwah, M Denewer, ...
    Advances in Hematology 2020 (1), 7695129 , 2020
    2020
    Citations: 5
  • Prevalence and impact of colony stimulating factor 3 receptor (CSF3R) mutations among Egyptian acute myeloid leukemia patients
    S Aref, M El-Ghonemy, T Abouzeid, A El-Sabbagh, M El-Baiomy
    Leukemia Research 38 (6), 722-725 , 2014
    2014
    Citations: 5